Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (321-330 of 438) with videos related to

Pageof 44
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2018
Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to CrizotinibLars-Arne Berger, Melanie Janning, Janna-Lisa Velthaus, et al.
Nature Communications|December 3, 2025
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinationsTianshi Lu, Habib Hamidi, Mark A Socinski, et al.
Discover Oncology|October 3, 2023
Preliminary results from the EMoLung clinical study showing early lung cancer detection by the LC scoreKarla Rubio, Jason M Müller, Aditi Mehta, et al.
The New England Journal of Medicine|June 5, 2018
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCMark A Socinski, Robert M Jotte, Federico Cappuzzo, et al.
Ebiomedicine|November 8, 2020
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNASteffen Dietz, Petros Christopoulos, Zhao Yuan, et al.
The Lancet. Oncology|June 6, 2015
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trialNick Thatcher, Fred R Hirsch, Alexander V Luft, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancerJoachim von Pawel, Robert Jotte, David R Spigel, et al.
The Lancet. Oncology|February 10, 2020
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialMarina C Garassino, Shirish Gadgeel, Emilio Esteban, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 12, 2022
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 TrialMarina C Garassino, Julien Mazieres, Martin Reck, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancerMartin Reck, Luis Paz-Ares, Paolo Bidoli, et al.
Pageof 44

Showing results (321-330 of 438) with videos related to

Sort By:
Pageof 44
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2018
Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to CrizotinibLars-Arne Berger, Melanie Janning, Janna-Lisa Velthaus, et al.
Nature Communications|December 3, 2025
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinationsTianshi Lu, Habib Hamidi, Mark A Socinski, et al.
Discover Oncology|October 3, 2023
Preliminary results from the EMoLung clinical study showing early lung cancer detection by the LC scoreKarla Rubio, Jason M Müller, Aditi Mehta, et al.
The New England Journal of Medicine|June 5, 2018
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCMark A Socinski, Robert M Jotte, Federico Cappuzzo, et al.
Ebiomedicine|November 8, 2020
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNASteffen Dietz, Petros Christopoulos, Zhao Yuan, et al.
The Lancet. Oncology|June 6, 2015
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trialNick Thatcher, Fred R Hirsch, Alexander V Luft, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancerJoachim von Pawel, Robert Jotte, David R Spigel, et al.
The Lancet. Oncology|February 10, 2020
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialMarina C Garassino, Shirish Gadgeel, Emilio Esteban, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 12, 2022
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 TrialMarina C Garassino, Julien Mazieres, Martin Reck, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancerMartin Reck, Luis Paz-Ares, Paolo Bidoli, et al.
Pageof 44